Galapagos NV (NASDAQ:GLPG) Q1 2024 Earnings Call Transcript

We believe we’ll be able to have a very broad access and really help a significant number of patients in the process in this area, particularly Richter’s transformation, which has a very significant unmet need. To the second part of the discussion regarding the Bristol data with Breyanzi. We of course welcome new therapies for patients in this significantly underserved disease. But there are some important observations. What they have presented is a single-arm study with no patients suffering from Richter’s transformation. In addition, the patients waited for a median vein-to-vein time of 36 days. And furthermore, the efficacy of less than 20% really does leave as an opportunity to improve this and really fundamentally impact on benefit to patients.

And so with that in mind, we are in a very strong position to know what data is out there. And clearly, with our unique platform, seven-day vein-to-vein, fresh to fresh, without any cryopreservation and the data that you have already seen, as well as the additional translational data, we feel very confident that we’re going to be able to contribute significantly to patients.

Operator: Now we’re going to take our last question for today. The question comes from line of Shan Hama from Jefferies.

Shan Hama: Just also on business development. Should we expect yield as a string of pearls throughout the year? Or is it preferable to have the outright acquisition of one company with a number of derisked late- assets?

Thad Huston: Yes. We continue to follow our plans to both assess the string of pearls, and we’re in discussions with a number of different companies to look at earlier, late, preclinical, early clinical assets. But we also assess larger transformations to try to have something that’s near term to the market as well. And we continue to evaluate a number of larger potential BD opportunities as well.

Sofie Van Gijsel: Thank you. That concludes today’s earnings call. Please feel free to reach out to the IR team if you still have questions. Our next financial results call is our H1 2024 call on August 2. Thank you all for participating, and have a great rest of your day.